Crucially, their findings revealed that Anlotinib blocks the CXCL11-EGF-EGFR feedback loop, implicating the AKT-mTOR pathway as part of this interaction, thereby offering a novel insight into the mechanism by which Anlotinib could exert its effects on both cancer and endothelial cells under hypoxic conditions. The gene discussed is EGF; the disease is cancer.